表紙:ファーマコビジランス市場規模:臨床試験段階別、サービスプロバイダー別、COVID-19の影響分析、地域別見通し、競合市場シェア・予測、2021年~2027年
市場調査レポート
商品コード
1033123

ファーマコビジランス市場規模:臨床試験段階別、サービスプロバイダー別、COVID-19の影響分析、地域別見通し、競合市場シェア・予測、2021年~2027年

Pharmacovigilance Market Size By Clinical Trial Phase, By Service Provider, COVID-19 Impact Analysis, Regional Outlook, Competitive Market Share & Forecast, 2021 - 2027

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 150 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
ファーマコビジランス市場規模:臨床試験段階別、サービスプロバイダー別、COVID-19の影響分析、地域別見通し、競合市場シェア・予測、2021年~2027年
出版日: 2021年10月14日
発行: Global Market Insights Inc.
ページ情報: 英文 150 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ファーマコビジランスの市場規模は、世界各地で行われているワクチン接種により、2027年までに急激な拡大を遂げると予測されています。

また、COVID-19の治療薬の開発が急ピッチで進められていることも、予測期間中の市場成長を後押しすると考えられます。

現在進行中のCOVID-19の大流行により、医薬品の安全性が注目され、ファーマコビジランス部門を強化する必要性が推進されています。COVID-19ワクチンの安全性に対する懸念が高まっていることに加え、世界的にワクチン接種の動きが活発化していることから、ファーマコビジランス市場の改善と新技術の採用の余地が大きくなっています。さらに、ファーマコビジランスの実施を支援するAI技術の採用は、正確でタイムリーな結果を提供することで医療インフラへの負担を軽減し、パンデミック時の市場導入を促進しました。

当レポートでは、ファーマコビジランス市場について調査し、市場の概要とともに、臨床試験段階別、サービスプロバイダー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

  • 調査手法
  • 市場の定義
  • 予測パラメータ
  • データ検証
  • データソース
    • 二次
    • 一次

第2章 エグゼクティブサマリー

  • ファーマコビジランス業界の全方位的概要、2016年~2027年(百万米ドル)
    • ビジネス動向
    • 臨床試験段階別動向
    • サービスプロバイダー別動向
    • 地域動向

第3章 ファーマコビジランス業界の洞察

  • 業界の細分化
  • 業界情勢、2016年~2027年
  • 業界への影響要因
    • 成長促進要因
    • 業界の潜在的リスクと課題
  • 成長可能性分析
    • 臨床試験段階別
    • サービスプロバイダー別
  • COVID-19の影響分析
  • 新しいビジネスモデル
  • ポーターの分析
  • 規制状況
  • ファーマコビジランスレポートシステム
  • 競合情勢
    • 企業のマトリクス分析
  • ファーマコビジランスサービスの情勢
  • PESTEL分析

第4章 ファーマコビジランス市場、臨床試験段階別

  • 主要なセグメントの動向
  • 前臨床
    • 市場規模、地域別、2016年~2027年(百万米ドル)
  • 第I相
    • 市場規模、地域別、2016年~2027年(百万米ドル)
  • 第II相
    • 市場規模、地域別、2016年~2027年(百万米ドル)
  • 第III相
    • 市場規模、地域別、2016年~2027年(百万米ドル)
  • 第IV相
    • 市場規模、地域別、2016年~2027年(百万米ドル)

第5章 ファーマコビジランス市場、サービスプロバイダー別

  • 主要なセグメントの動向
  • 社内
    • 市場規模、地域別、2016年~2027年(百万米ドル)
  • 契約アウトソーシング
    • 市場規模、地域別、2016年~2027年(百万米ドル)

第6章 ファーマコビジランス市場、地域別

  • 地域の主な動向
  • 北米
    • 国別の市場規模、2016年~2027年(百万米ドル)
    • 市場規模、臨床試験段階別、2016年~2027年(百万米ドル)
    • 市場規模、サービスプロバイダー別、2016年~2027年(百万米ドル)
    • 米国
    • カナダ
  • 欧州
    • 国別の市場規模、2016年~2027年(百万米ドル)
    • 市場規模、臨床試験段階別、2016年~2027年(百万米ドル)
    • 市場規模、サービスプロバイダー別、2016年~2027年(百万米ドル)
    • ドイツ
    • 英国
    • スペイン
    • イタリア
    • フランス
  • アジア太平洋地域
    • 国別の市場規模、2016年~2027年(百万米ドル)
    • 市場規模、臨床試験段階別、2016年~2027年(百万米ドル)
    • 市場規模、サービスプロバイダー別、2016年~2027年(百万米ドル)
    • 日本
    • 中国
    • インド
    • オーストラリア
  • ラテンアメリカ
    • 国別の市場規模、2016年~2027年(百万米ドル)
    • 市場規模、臨床試験段階別、2016年~2027年(百万米ドル)
    • 市場規模、サービスプロバイダー別、2016年~2027年(百万米ドル)
    • アルゼンチン
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • 国別の市場規模、2016年~2027年(百万米ドル)
    • 市場規模、臨床試験段階別、2016年~2027年(百万米ドル)
    • 市場規模、サービスプロバイダー別、2016年~2027年(百万米ドル)
    • 南アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • カタール
    • イスラエル

第7章 企業プロファイル

  • 競合ダッシュボード
  • Clinquest Group B V
  • Cognizant Technology Solutions Corporation
  • Ecron Acunova Ltd
  • Foresight Group International AG
  • IBM Corporation
  • ICON plc
  • iGATE Corporation(Capgemini)
  • InVentiv Health Clinical
  • IQVIA(QuintilesIMS)
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Novartis AG
  • PAREXEL International Corporation
  • Sanofi
  • Wipro
図表

Data Tables

  • TABLE 1. Global pharmacovigilance market, 2016 - 2027 (USD Million)
  • TABLE 2. Global pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 3. Global pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 4. Global pharmacovigilance market, by region, 2016 - 2027 (USD Million)
  • TABLE 5. Industry impact forces
  • TABLE 6. Pharmacovigilance regulatory initiatives
  • TABLE 7. Preclinical market size, by region, 2016 - 2027 (USD Million)
  • TABLE 8. Phase I market size, by region, 2016 - 2027 (USD Million)
  • TABLE 9. Phase II market size, by region, 2016 - 2027 (USD Million)
  • TABLE 10. Phase III market size, by region, 2016 - 2027 (USD Million)
  • TABLE 11. Phase IV market size, by region, 2016 - 2027 (USD Million)
  • TABLE 12. In-House market size, by region, 2016 - 2027 (USD Million)
  • TABLE 13. Contract outsourcing market size, by region, 2016 - 2027 (USD Million)
  • TABLE 14. North America pharmacovigilance market, by country, 2016 - 2027 (USD Million)
  • TABLE 15. North America pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 16. North America pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 17. U.S. pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 18. U.S. pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 19. Canada pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 20. Canada pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 21. Europe pharmacovigilance market, by country, 2016 - 2027 (USD Million)
  • TABLE 22. Europe pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 23. Europe pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 24. Germany pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 25. Germany pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 26. UK pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 27. UK pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 28. Spain pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 29. Spain pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 30. Italy pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 31. Italy pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 32. France pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 33. France pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 34. Asia Pacific pharmacovigilance market, by country, 2016 - 2027 (USD Million)
  • TABLE 35. Asia Pacific pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 36. Asia Pacific pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 37. Japan pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 38. Japan pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 39. China pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 40. China pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 41. India pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 42. India pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 43. Australia pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 44. Australia pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 45. Latin America pharmacovigilance market, by country, 2016 - 2027 (USD Million)
  • TABLE 46. Latin America pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 47. Latin America pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 48. Argentina pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 49. Argentina pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 50. Brazil pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 51. Brazil pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 52. Mexico pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 53. Mexico pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 54. MEA pharmacovigilance market, by country, 2016 - 2027 (USD Million)
  • TABLE 55. MEA pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 56. MEA pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 57. South Africa pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 58. South Africa pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 59. UAE pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 60. UAE pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 61. Saudi Arabia pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 62. Saudi Arabia pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 63. Qatar pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 64. Qatar pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
  • TABLE 65. Israel pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)
  • TABLE 66. Israel pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

Charts & Figures

  • FIG 1. Pharmacovigilance industry 360 degree synopsis, 2016 - 2027
  • FIG 2. Industry segmentation
  • FIG 3. Global pharmacovigilance market size, 2016 - 2027 (USD Million)
  • FIG 4. Growth potential analysis, by clinical trial phase
  • FIG 5. Growth potential analysis, by service provider
  • FIG 6. Types of pharmacovigilance outsourcing vendors
  • FIG 7. Porter's analysis
  • FIG 8. Company matrix analysis
  • FIG 9. PESTEL analysis
  • FIG 10. Key segmental trends, by clinical trial phase
  • FIG 11. Key segmental trends, by service provider
  • FIG 12. Key regional trends
  • FIG 13. Competitive dashboard
目次
Product Code: 853

The pharmacovigilance market is anticipated to register exponential growth by 2027 owing to the ongoing vaccination drives across the globe. In addition, surging emphasis on drug discoveries for the treatment of the COVID-19 disease is expected to further support market growth through the forecast period.

Pharmacovigilance refers to the science concerned with the assessment, detection, understanding, and prevention of adverse effects or other medication-related problems. The process of pharmacovigilance ensures the early detection of any pathological condition, such as an adverse drug reaction due to a particular drug, and prevent the occurrences of such effects, which has been favorable for industry expansion in recent years.

The ongoing COVID-19 outbreak has propelled the need for strengthening the pharmacovigilance sector by bringing drug safety into the spotlight. Growing concerns regarding the safety of the COVID-19 vaccine as well as fast-paced vaccination drives worldwide have emphasized the scope of improvement and adoption of new technologies in the pharmacovigilance market. Furthermore, the adoption of AI technologies to assist pharmacovigilance practices has reduced the burden on the healthcare infrastructure by offering accurate and timely results, which has augmented market uptake during the pandemic.

Notably, prominent companies have been implementing strategic initiatives to fortify their market standing, thereby enhancing overall business dynamics. For instance, in October 2021, IQVIA, a major firm in the life sciences space, inked a collaborative agreement with NRx Pharmaceuticals, a key biopharmaceutical company. As part of the deal, IQVIA agreed to provide NRx with pharmacovigilance services, along with medical information necessary for potential regulatory actions

The pharmacovigilance market has been segmented on the basis of service provider, clinical trials phase, and region. With respect to clinical trials phase, the market has further been classified into phase 1, phase 2, phase 3, phase 4, and pre clinical. The phase 2 sub-segment garnered a valuation of around USD 274.2 million in 2020 and is expected to progress at a robust pace over 2021-2027.

In terms of service provider, the pharmacovigilance market has been divided into contract outsourcing and in-house. The contract outsourcing sub-segment held a substantial share of more than 56.7% in the market in 2020 and is slated to witness optimistic growth through the forecast timeline.

From the regional point of view, the Latin America pharmacovigilance market is anticipated to exhibit significant growth by 2027, expanding at a CAGR of approximately 7.0% over the assessment period. Meanwhile, the Middle East & Africa pharmacovigilance market accounted for around 3.4% of the overall industry revenue in 2020 and is speculated to reach a sizable valuation by the end of 2027.

Table of Contents

Chapter 1 Methodology

  • 1.1 Methodology
  • 1.2 Market definitions
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Pharmacovigilance industry 360 degree synopsis, 2016 - 2027 (USD Million)
    • 2.1.1 Business trends
    • 2.1.2 Clinical trial phase trends
    • 2.1.3 Service provider trends
    • 2.1.4 Regional trends

Chapter 3 Pharmacovigilance Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2016 - 2027
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increase in adoption rate of outsourcing services in Asia Pacific
      • 3.3.1.2 Increasing consumption of drugs in developed regions
      • 3.3.1.3 Rise in adverse drug reactions (ADR) and drug toxicity
      • 3.3.1.4 Increasing acceptance of personalized medicine in developed regions
      • 3.3.1.5 Effective global harmonization practices
    • 3.3.2 Industry pitfalls and challenges
      • 3.3.2.1 Dearth of skilled personnel
      • 3.3.2.2 High risk associated with data security
  • 3.4 Growth potential analysis
    • 3.4.1 By clinical trial phase
    • 3.4.2 By service provider
  • 3.5 COVID-19 impact analysis
  • 3.6 New business models
  • 3.7 Porter's analysis
  • 3.8 Regulatory landscape
  • 3.9 Pharmacovigilance reporting system
  • 3.10 Competitive landscape
    • 3.10.1 Company matrix analysis
  • 3.11 Pharmacovigilance service landscape
  • 3.12 PESTEL analysis

Chapter 4 Pharmacovigilance Market, By Clinical Trial Phase

  • 4.1 Key segment trends
  • 4.2 Preclinical
    • 4.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.3 Phase I
    • 4.3.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.4 Phase II
    • 4.4.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.5 Phase III
    • 4.5.1 Market size, by region, 2016 - 2027 (USD Million)
  • 4.6 Phase IV
    • 4.6.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 5 Pharmacovigilance Market, By Service Provider

  • 5.1 Key segment trends
  • 5.2 In-house
    • 5.2.1 Market size, by region, 2016 - 2027 (USD Million)
  • 5.3 Contract outsourcing
    • 5.3.1 Market size, by region, 2016 - 2027 (USD Million)

Chapter 6 Pharmacovigilance Market, By Region

  • 6.1 Key regional trends
  • 6.2 North America
    • 6.2.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.2.2 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
    • 6.2.3 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.2.4 U.S.
      • 6.2.4.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.2.4.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.2.5 Canada
      • 6.2.5.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.2.5.2 Market size, by service provider, 2016 - 2027 (USD Million)
  • 6.3 Europe
    • 6.3.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.3.2 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
    • 6.3.3 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.3.4 Germany
      • 6.3.4.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.3.4.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.3.5 UK
      • 6.3.5.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.3.5.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.3.6.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.3.7 Italy
      • 6.3.7.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.3.7.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.3.8 France
      • 6.3.8.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.3.8.2 Market size, by service provider, 2016 - 2027 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.4.2 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
    • 6.4.3 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.4.4 Japan
      • 6.4.4.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.4.4.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.4.5 China
      • 6.4.5.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.4.5.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.4.6 India
      • 6.4.6.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.4.6.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.4.7 Australia
      • 6.4.7.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.4.7.2 Market size, by service provider, 2016 - 2027 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.5.2 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
    • 6.5.3 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.5.4 Argentina
      • 6.5.4.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.5.4.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.5.5 Brazil
      • 6.5.5.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.5.5.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.5.6 Mexico
      • 6.5.6.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.5.6.2 Market size, by service provider, 2016 - 2027 (USD Million)
  • 6.6 MEA
    • 6.6.1 Market size, by country, 2016 - 2027 (USD Million)
    • 6.6.2 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
    • 6.6.3 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.6.4 South Africa
      • 6.6.4.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.6.4.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.6.5 UAE
      • 6.6.5.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.6.5.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.6.6 Saudi Arabia
      • 6.6.6.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.6.6.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.6.7 Qatar
      • 6.6.7.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.6.7.2 Market size, by service provider, 2016 - 2027 (USD Million)
    • 6.6.8 Israel
      • 6.6.8.1 Market size, by clinical trial phase, 2016 - 2027 (USD Million)
      • 6.6.8.2 Market size, by service provider, 2016 - 2027 (USD Million)

Chapter 7 Company Profiles

  • 7.1 Competitive dashboard
  • 7.2 Clinquest Group B V
    • 7.2.1 Business overview
    • 7.2.2 Financial data
    • 7.2.3 Product landscape
    • 7.2.4 Strategic outlook
    • 7.2.5 SWOT analysis
  • 7.3 Cognizant Technology Solutions Corporation
    • 7.3.1 Business overview
    • 7.3.2 Financial data
    • 7.3.3 Product landscape
    • 7.3.4 Strategic outlook
    • 7.3.5 SWOT analysis
  • 7.4 Ecron Acunova Ltd
    • 7.4.1 Business overview
    • 7.4.2 Financial data
    • 7.4.3 Product landscape
    • 7.4.4 Strategic outlook
    • 7.4.5 SWOT analysis
  • 7.5 Foresight Group International AG
    • 7.5.1 Business overview
    • 7.5.2 Financial data
    • 7.5.3 Product landscape
    • 7.5.4 Strategic outlook
    • 7.5.5 SWOT analysis
  • 7.6 IBM Corporation
    • 7.6.1 Business overview
    • 7.6.2 Financial data
    • 7.6.3 Product landscape
    • 7.6.4 Strategic outlook
    • 7.6.5 SWOT analysis
  • 7.7 ICON plc
    • 7.7.1 Business overview
    • 7.7.2 Financial data
    • 7.7.3 Product landscape
    • 7.7.4 Strategic outlook
    • 7.7.5 SWOT analysis
  • 7.8 iGATE Corporation (Capgemini)
    • 7.8.1 Business overview
    • 7.8.2 Financial data
    • 7.8.3 Product landscape
    • 7.8.4 Strategic outlook
    • 7.8.5 SWOT analysis
  • 7.9 InVentiv Health Clinical
    • 7.9.1 Business overview
    • 7.9.2 Financial data
    • 7.9.3 Product landscape
    • 7.9.4 Strategic outlook
    • 7.9.5 SWOT analysis
  • 7.10 IQVIA (QuintilesIMS)
    • 7.10.1 Business overview
    • 7.10.2 Financial data
    • 7.10.3 Product landscape
    • 7.10.4 Strategic outlook
    • 7.10.5 SWOT analysis
  • 7.11 ITclinical
    • 7.11.1 Business overview
    • 7.11.2 Financial data
    • 7.11.3 Product landscape
    • 7.11.4 Strategic outlook
    • 7.11.5 SWOT analysis
  • 7.12 Laboratory Corporation of America Holdings
    • 7.12.1 Business overview
    • 7.12.2 Financial data
    • 7.12.3 Product landscape
    • 7.12.4 Strategic outlook
    • 7.12.5 SWOT analysis
  • 7.13 Novartis AG
    • 7.13.1 Business overview
    • 7.13.2 Financial data
    • 7.13.3 Product landscape
    • 7.13.4 Strategic outlook
    • 7.13.5 SWOT analysis
  • 7.14 PAREXEL International Corporation
    • 7.14.1 Business overview
    • 7.14.2 Financial data
    • 7.14.3 Product landscape
    • 7.14.4 Strategic outlook
    • 7.14.5 SWOT analysis
  • 7.15 Sanofi
    • 7.15.1 Business overview
    • 7.15.2 Financial data
    • 7.15.3 Product landscape
    • 7.15.4 Strategic outlook
    • 7.15.5 SWOT analysis
  • 7.16 Wipro
    • 7.16.1 Business overview
    • 7.16.2 Financial data
    • 7.16.3 Product landscape
    • 7.16.4 Strategic outlook
    • 7.16.5 SWOT analysis